Literature DB >> 29053874

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Alexandre Bejanin1, Daniel R Schonhaut1, Renaud La Joie1, Joel H Kramer1, Suzanne L Baker2, Natasha Sosa1, Nagehan Ayakta1, Averill Cantwell1, Mustafa Janabi2, Mariella Lauriola1, James P O'Neil2, Maria L Gorno-Tempini1, Zachary A Miller1, Howard J Rosen1, Bruce L Miller1, William J Jagust2,3, Gil D Rabinovici1,2,3.   

Abstract

Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau pathology is also intimately associated with neurodegeneration and amyloid pathology. The aim of the present study was therefore to assess whether grey matter atrophy and amyloid pathology contribute to the relationship between tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disease. We included 40 amyloid-positive patients meeting criteria for mild cognitive impairment due to Alzheimer's disease (n = 5) or probable Alzheimer's disease dementia (n = 35). Twelve patients additionally fulfilled the diagnostic criteria for posterior cortical atrophy and eight for logopenic variant primary progressive aphasia. All participants underwent 3 T magnetic resonance imaging, amyloid (11C-PiB) positron emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic and semantic memory, language, executive and visuospatial functions assessment. Raw cognitive scores were converted to age-adjusted Z-scores (W-scores) and averaged to compute composite scores for each cognitive domain. Independent regressions were performed between 18F-AV-1451 binding and each cognitive domain, and we used the Biological Parametric Mapping toolbox to further control for local grey matter volumes, 11C-PiB uptake, or both. Partial correlations and causal mediation analyses (mediation R package) were then performed in brain regions showing an association between cognition and both 18F-AV-1451 uptake and grey matter volume. Our results showed that decreased cognitive performance in each domain was related to increased 18F-AV-1451 binding in specific brain regions conforming to established brain-behaviour relationships (i.e. episodic memory: medial temporal lobe and angular gyrus; semantic memory: left anterior temporal regions; language: left posterior superior temporal lobe and supramarginal gyrus; executive functions: bilateral frontoparietal regions; visuospatial functions: right more than left occipitotemporal regions). This pattern of regional associations remained essentially unchanged-although less spatially extended-when grey matter volume or 11C-PiB uptake maps were added as covariates. Mediation analyses revealed both direct and grey matter-mediated effects of 18F-AV-1451 uptake on cognitive performance. Together, these results show that tau pathology is related in a region-specific manner to cognitive impairment in Alzheimer's disease. These regional relationships are weakly related to amyloid burden, but are in part mediated by grey matter volumes. This suggests that tau pathology may lead to cognitive deficits through a variety of mechanisms, including, but not restricted to, grey matter loss. These results might have implications for future therapeutic trials targeting tau pathology.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; amyloid; atrophy; cognitive impairment; tau

Mesh:

Substances:

Year:  2017        PMID: 29053874      PMCID: PMC5841139          DOI: 10.1093/brain/awx243

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  52 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Authors:  N Maritza Dowling; Sterling C Johnson; Carey E Gleason; William J Jagust
Journal:  Neuroimage       Date:  2014-10-29       Impact factor: 6.556

Review 3.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

4.  In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.

Authors:  Julian Dronse; Klaus Fliessbach; Gérard N Bischof; Boris von Reutern; Jennifer Faber; Jochen Hammes; Georg Kuhnert; Bernd Neumaier; Oezguer A Onur; Juraj Kukolja; Thilo van Eimeren; Frank Jessen; Gereon R Fink; Thomas Klockgether; Alexander Drzezga
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

7.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

Review 8.  Are AD-Typical Regions the Convergence Point of Multiple Pathologies?

Authors:  Sylvia Villeneuve; Miranka Wirth; Renaud La Joie
Journal:  Front Aging Neurosci       Date:  2015-03-25       Impact factor: 5.750

9.  Are tau aggregates toxic or protective in tauopathies?

Authors:  Catherine M Cowan; Amrit Mudher
Journal:  Front Neurol       Date:  2013-08-13       Impact factor: 4.003

10.  Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease.

Authors:  Laure Saint-Aubert; Ove Almkvist; Konstantinos Chiotis; Rita Almeida; Anders Wall; Agneta Nordberg
Journal:  Alzheimers Res Ther       Date:  2016-09-29       Impact factor: 6.982

View more
  176 in total

Review 1.  Biomarkers for neurodegenerative diseases.

Authors:  Oskar Hansson
Journal:  Nat Med       Date:  2021-06-03       Impact factor: 53.440

2.  Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.

Authors:  Nicolai Franzmeier; Anna Rubinski; Julia Neitzel; Yeshin Kim; Alexander Damm; Duk L Na; Hee Jin Kim; Chul Hyoung Lyoo; Hana Cho; Sofia Finsterwalder; Marco Duering; Sang Won Seo; Michael Ewers
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

3.  Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau.

Authors:  Syed Faraz Kazim; Joon Ho Seo; Riccardo Bianchi; Chloe S Larson; Abhijeet Sharma; Robert K S Wong; Kirill Y Gorbachev; Ana C Pereira
Journal:  eNeuro       Date:  2021-04-23

Review 4.  From simultaneous to synergistic MR-PET brain imaging: A review of hybrid MR-PET imaging methodologies.

Authors:  Zhaolin Chen; Sharna D Jamadar; Shenpeng Li; Francesco Sforazzini; Jakub Baran; Nicholas Ferris; Nadim Jon Shah; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2018-08-04       Impact factor: 5.038

Review 5.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

6.  Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline.

Authors:  Kamalini G Ranasinghe; Jungho Cha; Leonardo Iaccarino; Leighton B Hinkley; Alexander J Beagle; Julie Pham; William J Jagust; Bruce L Miller; Katherine P Rankin; Gil D Rabinovici; Keith A Vossel; Srikantan S Nagarajan
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

7.  MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus.

Authors:  Zall Hirschstein; Gautam Reddy Vanga; Guirong Wang; Zachary M Novakovic; Patricia Grasso
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-07-29       Impact factor: 3.770

8.  Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease.

Authors:  Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2019-08-01       Impact factor: 21.566

9.  Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.

Authors:  Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

Review 10.  Early-onset Alzheimer Disease and Its Variants.

Authors:  Mario F Mendez
Journal:  Continuum (Minneap Minn)       Date:  2019-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.